In July, the most popular stories from Interventional News included a survey highlighting a significant lack of awareness among women surrounding uterine artery fibroid treatment options; outcomes of a secondary investigational device exemption (IDE) analysis of the aVeNEW trial data; results from the EMBO-01 trial as presented at 2024 Society of NeuroInterventional Surgery (SNIS) annual meeting and several more.
Following her presentation on uterine artery embolization (UAE) for fibroids at the Global Embolisation Oncology Symposium Technologies (GEST; 16–19 May, New York, USA), Abeer AlDhawi (Riyadh, Saudi Arabia), describes the “significant relief” that can be provided to patients through this minimally invasive procedure.
2. Survey finds women with uterine fibroids offered hysterectomies over minimally invasive treatments
A recent survey conducted by The Harris Poll on behalf of the Society of Interventional Radiology (SIR) has revealed that more than half (53%) of women diagnosed with uterine fibroids were primarily offered a hysterectomy. In contrast, fewer than 20% were presented with less invasive alternatives such as over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs; 19%), uterine fibroid embolization (UFE; 17%), oral contraceptives (17%), and endometrial ablation (17%).
3. Thrombectomy gold rush set to follow ATTRACT study, experts argue
At the recent Endo Vascular Access (EVA) meeting (14–15 June, Patras, Greece), Ziv Haskal (University of Virginia School of Medicine, Charlottesville, USA) spoke to Timothy Clark (Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA) about what they referred to as the “gold rush” of thrombectomy devices for large-calibre blood vessels.
4. Microbot Medical announces first patient treated with endovascular robotic surgical system
Microbot Medical has announced that Baptist Hospital of Miami, USA—which includes Miami Cardiac & Vascular Institute and Miami Cancer Institute—has completed its first clinical procedure in a patient utilising the Liberty endovascular robotic surgical system.
5. Transit Scientific announces first case using embolic delivery microcatheter
Transit Scientific announces the successful clinical deployment of XO Cath, an embolic delivery microcatheter intended for interventional procedures.
6. IASIOS awards first institution centre of excellence seal
The International Accreditation System for Interventional Oncology Services (IASIOS) has announced that the Hôpitaux Universitaires de Strasbourg in France has been designated as the world’s first centre of excellence.
7. AVeNEW trial shows superior AVF target lesion patency with covered stent placement
“Study design is critically important when interpreting outcomes,” said Bart Dolmatch (Mountain View Hospital, Mountain View, USA) in his evaluation of the “disconnect” between target lesion primary patency (TLPP) and access circuit primary patency (ACPP) analysing AVeNEW study data at this year’s Endo Vascular Access (EVA) meeting (14–15 June, Patras, Greece).
8. Novel liquid embolic agent meets primary feasibility and safety endpoints in EMBO-01 trial
Arsenal Medical has announced that NeoCast—a first-of-its-kind, shear-responsive liquid embolic material designed for deep distal penetration—met its primary feasibility and safety endpoints in the open-label, multicentre, prospective EMBO-01 clinical trial. These data were presented earlier today at the 2024 Society of NeuroInterventional Surgery (SNIS) annual meeting (22–26 July, Colorado Springs, USA).
A recent study suggests that endovascular treatment of the common femoral artery (CFA) is associated with an increased rate of long-term CFA-specific reintervention, regardless of indication. Nicholas Wells, a medical student at Yale School of Medicine in New Haven, USA, presented this and other key findings from a tertiary care centre analysis of open and endovascular treatment of the CFA at the 2024 Vascular Annual Meeting (VAM; 19–22 June, Chicago, USA).
10. Inspire Medical announces CE mark approval for Inspire IV device
Inspire Medical Systems has secured the CE mark certification for full-body magnetic resonance imaging (MRI) compatibility for its Inspire IV neurostimulator device under the European Union’s (EU) medical device regulation (MDR).
